Xeris Biopharma Holdings (XERS) Stock Overview
A commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
XERS Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Xeris Biopharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.14 |
| 52 Week High | US$9.29 |
| 52 Week Low | US$2.82 |
| Beta | 0.90 |
| 1 Month Change | 22.36% |
| 3 Month Change | 78.87% |
| 1 Year Change | 200.66% |
| 3 Year Change | 637.10% |
| 5 Year Change | n/a |
| Change since IPO | 287.29% |
Recent News & Updates
There's Reason For Concern Over Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Massive 26% Price Jump
Oct 16
Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy
Sep 05Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Analysts Are Pretty Bullish On The Stock After Recent Results
Aug 10Recent updates
There's Reason For Concern Over Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Massive 26% Price Jump
Oct 16Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy
Sep 05Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Analysts Are Pretty Bullish On The Stock After Recent Results
Aug 10A Piece Of The Puzzle Missing From Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) 25% Share Price Climb
Jul 15
Advancing Recorlev, Gvoke And XP-8121 Will Drive Future Demand
Strategic investments in Recorlev and untapped Gvoke markets may significantly boost long-term revenue, aligning with medical guidelines to meet growing patient demands.Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator
Mar 16Investors Appear Satisfied With Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Prospects As Shares Rocket 34%
Mar 16An Intrinsic Calculation For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Suggests It's 47% Undervalued
Mar 07Some Shareholders Feeling Restless Over Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) P/S Ratio
Jan 30Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
Oct 25Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks
Sep 07Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company
Jun 04Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Mar 30Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results
Mar 09Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up
Mar 06Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth
Jan 05Xeris Pharmaceuticals Q2 2022 Earnings Preview
Aug 09Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal
Aug 01Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven
May 21Xeris Continues To Execute And Build Long-Term Value Potential
Feb 22Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition
Dec 20Shareholder Returns
| XERS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 11.6% | -1.6% | -1.2% |
| 1Y | 200.7% | -7.0% | 15.1% |
Return vs Industry: XERS exceeded the US Pharmaceuticals industry which returned -7% over the past year.
Return vs Market: XERS exceeded the US Market which returned 15.1% over the past year.
Price Volatility
| XERS volatility | |
|---|---|
| XERS Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: XERS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XERS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 394 | John Shannon | www.xerispharma.com |
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism.
Xeris Biopharma Holdings, Inc. Fundamentals Summary
| XERS fundamental statistics | |
|---|---|
| Market cap | US$1.50b |
| Earnings (TTM) | -US$32.00m |
| Revenue (TTM) | US$246.03m |
Is XERS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XERS income statement (TTM) | |
|---|---|
| Revenue | US$246.03m |
| Cost of Revenue | US$43.70m |
| Gross Profit | US$202.33m |
| Other Expenses | US$234.33m |
| Earnings | -US$32.00m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 82.24% |
| Net Profit Margin | -13.01% |
| Debt/Equity Ratio | -1,132.5% |
How did XERS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/16 21:51 |
| End of Day Share Price | 2025/10/16 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xeris Biopharma Holdings, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Brandon Folkes | H.C. Wainwright & Co. |